RESEARCH & DEVELOPMENT
Beyond innovative technology, our drug discovery process is structured to streamline and expedite the drug development process through leveraging the extensive experience of the team and the multi-indication applications of our compounds. From concept-to-development, approval and beyond - our systematic approach is geared toward moving potential drugs for traumatic brain injury (TBI), Alzheimer's disease (AD) and other neurodegenerative diseases from the laboratory to market as quickly and efficiently as possible.
Consequently, the efficient reversal of the over expression of this key enzymes can completely mitigate all of these pathways at once and prevent the neuronal destruction that they mediate. Doing so significantly improves measures of memory deficit and neuro-motor dysfunction in TBI and AD animal models, respectively. The inhibition of these protease not only reduces neuro-inflammation, but also provides potent neuronal protection by multiple mechanisms. Data from TBI and AD models using cathepsin B knock-out animals indicate that this protease plays a dominant role at this toxic intersection and suggests that its inhibition should not have undesired consequences. Lead Compound Cathepsin B activity is significantly elevated in TBI and AD. This enzyme has been well studied with respect to its contribution to pathways leading to caspase activation and programmed cell death (apoptosis) of the neuron, to inflammatory pathways that include TNF-a, Il-1β and metallo-proteinase activation, and to tissue necrosis. ALSP’s lead compound, ALP-495, is a potent inhibitor of cathepsin B. Elimination of the drug is primarily through the kidney and the gut without multi-dosing accumulation. Extensive work with ALP-495-related tool compounds suggests that this class of compounds has a wide therapeutic window.